Neurocrine Biosciences, Inc. (NBIX)

Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$150.57-3.84%As of 2026-11-22 · USD
Last session low $150.24Last session high $158.25
52-week low $122.1452-week high $186.12
Market cap
$15.24B
Sector
Healthcare
P/E (TTM)
22.3x

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)44.9In the neutral range (30 to 70)
MACD (12, 26, 9)3.75Below its signal line (5.13); histogram -1.38
Bollinger %B (20, 2)28%Inside the bands (139.57 to 178.73)
SMA 20159.15Price is 5.4% below
SMA 50149.07Price is 1.0% above
SMA 200149.45Price is 0.7% above
ATR (20)3.47% of priceAverage true range per day
52-week position44%In the middle of the 122.14 to 186.12 range

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Insider filings, 90 daysNo purchases and 6 sales (about $3.2M).
Latest fiscal yearEnded 2025-12-31: revenue of $2.86B and an operating margin of 22.3%.

More in Drug Manufacturers - Specialty & Generic